Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

BACKGROUND: Metastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors. This phase II trial evaluates the efficacy and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lum, Lawrence G., Al-Kadhimi, Zaid, Deol, Abhinav, Kondadasula, Vidya, Schalk, Dana, Tomashewski, Elyse, Steele, Patricia, Fields, Kristie, Giroux, Melissa, Liu, Qin, Flaherty, Lawrence, Simon, Michael, Thakur, Archana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202097/
https://www.ncbi.nlm.nih.gov/pubmed/34117114
http://dx.doi.org/10.1136/jitc-2020-002194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202097/
https://www.ncbi.nlm.nih.gov/pubmed/34117114
http://dx.doi.org/10.1136/jitc-2020-002194

Ejemplares similares